卡巴他赛Jevtana（cabazitaxel）

[Jimin Pharmaceutical Guide] Cabazitaxel Jevtana is suitable for prostate cancer. This type of prostate cancer patients have failed treatment with docetaxel-containing treatment regimens and have refractory metastatic prostate cancer.

This product is an injection with a specification of 60mg/1.5ml. The recommended dose is one injection every 3 weeks.

Cabazitaxel Jevtana injection is the latest generation of semi-synthetic taxane drugs that easily penetrate the blood-brain barrier. Multiple in vitro and in vivo studies have shown that it has good anti-tumor effects. Cabazitaxel Jevtana was developed by Sanofi Pharmaceuticals and approved for sale by the US FDA.